AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA BioTech ADIL Top Biotech Gainers: VRXA Begins A New Chapter, ADIL Opens Wallet, PGEN, PCSA On Watch... June 11, 2026 — 11:54 pm EDT Written by RTTNews.com for RTTNews -> (RTTNews) - Today's top gainers were led by Australia-based Gelteq, which develops a novel ingestible gel-based drug delivery platform; Adial Pharmaceuticals, which announced the acquisition of Azora Therapeutics as part of its pipeline expansion strategy; Precigen, which is drawing renewed attention as its lead asset PAPZIMEOS gains commercial traction; and Eloxx, following its recent uplisting to Nasdaq, among others. Read on… GELS on the Move Shares of Australia-based Gelteq (GELS), a biotechnology company that has developed a novel drug delivery platform in an ingestible gel form, jumped over 197% on Thursday in the absence of any specific news. Late last month, the company commenced its first clinical trial for an antiparasitic drug candidate powered by Gelteq technology and is working toward a potential FDA submission this year. GELS closed Thursday's trading at $1.53, up 197.38%. VRXA Begins a New Chapter VERAXA Biotech (VRXA), on Thursday, successfully closed its previously announced business combination with Voyager Acquisition Corp., resulting in the formation of VERAXA Biotech AG. The shares have begun trading (June 11, 2026) on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, which is designed to selectively target cancer cells while sparing healthy tissue. VRXA closed Thursday's trading at $24.79, up 32.92%. ADIL Acquires Azora Adial Pharmaceuticals Inc. (ADIL), on Thursday, announced the acquisition of Azora Therapeutics, a biopharmaceutical company developing treatments for serious inflammatory diseases, and up to $64 million in financing. The acquisition adds AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis, to Adial's pipeline. AT177 is currently in IND-enabling studies, with a Phase I clinical trial planned for 2027. The financial terms of the acquisition were not disclosed. The $64 million financing, led by Coastlands Capital, is composed of an initial upfront financing of approximately $32 million in gross proceeds and the potential for up to an additional $32 million in gross proceeds upon Phase 1 clinical study initiation of AT177. ADIL closed Thursday's trading at $2.98, up 37.96%. MBX Turns Heads MBX Biosciences Inc. (MBX) will present one-year open-label extension (OLE) data from the Phase 2 trial of once-weekly its lead drug candidate Canvuparatide, for chronic hypoparathyroidism, at the 3rd Parathyroid Summit during ENDO 2026 on Friday, June 12, 2026. Full results from the 12-week Avail Phase 2 trial of once-weekly Canvuparatide will be presented in an oral presentation at ENDO 2026 at 3:00 pm CT on Saturday, June 13, 2026. MBX remains on track to initiate a Phase 3 confirmatory trial of once-weekly Canvuparatide in chronic hypoparathyroidism in Q3 2026. MBX closed Thursday's trading at $37.25, up 20.20%. PCSA On Watch Processa Pharmaceuticals Inc.'s (PCSA) CEO, George Ng, and its Founder and Chief Business & Strategy Officer, Patrick Lin, will attend the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, California. The company's clinical pipeline, including the ongoing Phase 2 study evaluating NGC-Cap in patients with advanced or metastatic breast cancer, is expected to be discussed during the conference. NGC-Cap, the company's lead asset, is designed to increase systemic exposure to active cancer-killing anabolite metabolites while reducing formation of toxic catabolite metabolites, potentially improving the therapeutic index of Capecitabine-based therapy. Preliminary Phase 2 data have demonstrated that NGC-Cap increases exposure to capecitabine's cancer-killing metabolites while maintaining a safety profile comparable to standard capecitabine monotherapy. The company expects to complete a formal interim analysis from the first 20 patients enrolled in early 2026. PCSA closed Thursday's trading at $2.37, up 19.70%. PGEN's Commercial Chapter Gains Momentum Precigen Inc. (PGEN), which transitioned to a commercial-stage company last August, following the launch of PAPZIMEOS, soared more than 16% on Thursday. PAPZIMEOS, which was approved by the FDA in August 2025, is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of adults with recurrent respiratory papillomatosis. Acco